Michael Molyneaux MD MBA
Chief Medical Officer
Investors: Stephanie Carrington
Tel: +1 646 277 1282
Media: Mark CorbaeTel: 203-682-8288Email: Mark.Corbae@icrinc.com
Having put on the backburner its one-time lead drug-development program in ocular neovascularization disorders, Sirnaomics is now focusing on an siRNA-based treatment for scarless wound healing and anticipates moving the drug into phase I testing.